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ABSTRACT
Background: This study was aimed to assess the risk of breast cancer associated with exposure to insu-
lin glargine in women with type 2 diabetes and evaluate whether the pattern of risk concurs with the
hypothesized trend of an increase in risk with longer duration of use, taking into account previous
cumulative exposure to other types of insulin.
Methods: We performed a restrospective cohort study (2002–2013) in the Clinical Practice Research
Datalink among adult female patients with a first ever insulin prescription (n¼ 12 468). Time-dependent
exposure measures were used to assess associations with duration of use of: (1) other insulin types
before glargine was first prescribed (i.e. among switchers); and (2) of glargine during follow-up.
Analyses were performed separately for insulin-na€ıve glargine users and patients switched to glargine.
Cox proportional hazards models were used to derive p-trends, hazard ratios (HR) and 95% confidence
intervals (CI) for breast cancer associated with glargine use.
Results: During 66 151 person years, 186 breast cancer cases occurred; 76 in glargine users (3.0/1000
years) and 110 in users of other insulins (2.7/1000 years). Among insulin-na€ıve women, no association
with cumulative glargine use was observed (p-trend¼ 0.91), even after5 years (HR¼ 1.06, 95% CI
0.48–2.33). Among switchers, a linear trend with years of prior exposure to other insulins was found
(p-trend¼ 0.02). An increased risk was observed in glargine users with extensive (>3 years) past expos-
ure to other insulins (HR¼ 3.17, 95% CI 1.28–7.84). A non-significant trend with cumulative glargine
exposure was found among switchers (p-trend¼ 0.24).
Conclusions: Exposure to glargine was not associated with an increased breast cancer risk in insulin-
na€ıve patients. Exposure to other insulins prior to the start of glargine appears to be relevant when
studying breast cancer risk associated with glargine use.
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In women, type 2 diabetes is associated with an increased
risk of breast cancer [1,2]. In 2009, a number of observational
studies emerged that linked the use of long-acting insulin
glargine to an increased cancer incidence among women
with type 2 diabetes, in particular breast cancer [3–5]. Since
then, treatment with insulin glargine has been studied inten-
sively for its possible association with an increased breast
cancer risk [6,7]. However, observational studies among insu-
lin users are complicated by the fact that all insulins to some
extent act as a growth stimulating factor [8].
Human insulin acts as a growth promoting agent, stimulat-
ing breast cancer cell growth and inhibiting apoptosis in vitro
[9]. Differences in mitogenic potency between human insulin
and insulin analogs on breast cancer cells have been shown
in vitro [8,10]. Insulin glargine specifically appears to have
an increased mitogenic potency [8,10], possibly related to
its increased affinity for the insulin-like growth factor-1 recep-
tor [11]. Overall, results from cell studies indicate a cell
growth stimulating effect, rather than a carcinogenic effect
[12]. Consequently, the risk of breast cancer is expected to
increase with longer duration of exposure.
However, the majority of epidemiological studies con-
ducted did not assess trends in breast cancer risk with dur-
ation of glargine use. Of the more detailed second generation
studies, only five assessed cancer risk in relation to cumula-
tive exposure measures [13–17]. All of them evaluated dur-
ation of glargine use among insulin-na€ıve users separately
and only one of the five studies observed a significant
increased breast cancer risk associated with high cumulative
exposure to glargine [14]. However, all studies lacked suffi-
cient follow-up to robustly estimate cancer risk beyond three
years of cumulative duration of use [13–17]. Therefore, further
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study of breast cancer risk with long-term glargine use
(>3 years) remains necessary.
Of the two studies that included prevalent insulin users
who switched to glargine, one observed an increased breast
cancer risk after at least five years of cumulative glargine use
[13]. The other did not find an association with duration of
use, but was unable to study effects of long-term glargine use
due to a median duration of glargine use of 1.2 years [14].
Both studies determined exposure to glargine at baseline
(intention-to-treat) and were limited by left-truncated data,
which resulted in misclassification of duration of exposure
and potential underestimation of past exposure to other insu-
lins prior to the switch to glargine. Moreover, neither study
was able to determine how the duration of non-glargine insu-
lin use before cohort entry modifies the effect of glargine use.
The aim of our study was to assess the risk of breast can-
cer associated with exposure to insulin glargine in women
with type 2 diabetes and evaluate whether the pattern of risk
concurs with the hypothesized trend of an increase in risk
with longer duration of use, taking into account previous
cumulative exposure to other types of insulin.
Methods
Source of data
Data were obtained from the Clinical Practice Research
Datalink (CPRD), which comprises electronic medical records
from British general practitioners since 1987 [18]. The accur-
acy and completeness of CPRD data have been well validated
in previous studies [19]. Currently, CPRD includes approxi-
mately 7% of the total UK population [18]. The protocol of
this study was approved by CPRD’s Independent Scientific
Advisory Committee.
Study population
For this retrospective cohort study, we used a ‘new user’ design
with incident insulin users. All women (18 years) with at least
one prescription for any type of insulin in CPRD during the
inclusion period were eligible. To ensure a minimal follow-up
period of approximately three years between cohort entry and
the end of data collection (1 October 2013), the inclusion period
stretched from 1 September 2002 – the marketing date of glar-
gine in the UK – to 31 December 2010. The index date was
defined as the date of the first recorded prescription for any
type of insulin within the inclusion period. On the index date, all
subjects were required to have at least one year of up-to-stand-
ard patient history in CPRD without any recorded history of
insulin use to improve the validity of the ‘new user’ design.
Patients considered to have type 1 diabetes were excluded.
These were patients without any use of non-insulin antidiabetic
drugs (NIADs) in the year prior to cohort entry who: 1) had a
recorded diagnosis for type 1 diabetes before cohort entry; or
2) were under 30 years of age at cohort entry. Subjects with a
history of breast cancer at baseline were also excluded. All sub-
jects were followed from the index date until the outcome of
interest, end of data collection, date of migration out of the
CPRD population, or death, whichever came first.
Exposure to insulins
We used a time-dependent design (Figure 1) to define expos-
ure. For all patients, the follow-up period after the index date
was divided into discrete 30-day intervals. Exposure to glar-
gine (‘any use’) was then defined as a prescription for glar-
gine on the start date or at any time before the start of each
interval. Patients with a prescription for non-glargine insulin
(i.e. any insulin type except glargine) at cohort entry could
become exposed during follow-up if a prescription for glar-
gine was recorded (‘switchers’). Current exposure to glargine
and non-glargine insulins was defined as a prescription on
the start date or in the three months prior to the start of
each 30-day interval.
In a stepwise manner, we added time-dependent cumula-
tive measures for duration of use of: (1) glargine during fol-
low-up; and (2) non-glargine insulins before the initiation of
glargine therapy. In a final model (3), we studied breast can-
cer risk associated with cumulative duration of glargine use
separately among insulin-na€ıve glargine users and users of
glargine with prior use of other insulin types (Figure 1).
Cumulative duration of use calculations were based on the
number of days of ‘current exposure’.
Duration of use of glargine during follow-up was deter-
mined at the start of each 30-day interval and classified as
‘0–1 years’, ‘1–3 years’, or ‘>3 years’ (Figure 1a), based on the
total number of days of current exposure to glargine.
Consequently, cumulative exposure to glargine could only
increase or remain stable over time.
In switchers, cumulative number of days of past exposure
to non-glargine insulins was calculated at the start date of
glargine treatment. Here, we differentiated between insulin-
na€ıve patients at the start of glargine treatment, and switch-
ers with a cumulative duration of past exposure to non-glar-
gine insulins of ‘0–3 years’ and ‘>3 years’ (Figure 1b).
In our final model, we performed separate analyses regard-
ing associations with duration of glargine exposure during fol-
low-up among insulin-na€ıve patients and prevalent insulin
users switched to glargine (Figure 1c). In all models, we quan-
tified the risk of breast cancer associated with glargine use as
compared to ‘never use’ of glargine; as the study was per-
formed among insulin users, person time on glargine was
compared to person time on other insulins.
Study outcome
All subjects were followed up for the occurrence of a first
medical diagnosis of breast cancer in CPRD (see
Supplemental Table A for the used medical codes, available
online at http://www.informahealthcare.com). Completeness
of case ascertainment for breast cancer in CPRD is high as
compared to the national cancer registry data [20]. A recent
study found a concordance rate of 89.8% with cancer regis-
tries and a subsequent 6.4% of the records were in agree-
ment with hospital records or death certificates [20].
Covariates
Models were adjusted for potential confounders in a time-
dependent manner. Age was determined as the year
852 P. J. H. L. PEETERS ET AL.
difference between calendar year and year of birth at the
start of each 30-day interval. A history of cancer other than
breast cancer (or non-melanoma skin cancer) and oophorec-
tomy was determined as a medical diagnosis at any time
before the start of each interval. Smoking status (yes or no)
and alcohol use (yes or no) were determined at cohort entry
and subsequently updated during follow-up at the start of
each interval. Current use of comedication (i.e. hormone
replacement therapy, statins, metformin, sulfonylureas, and
glitazones) was determined as a prescription in the past 180
days prior to the start of each interval. For body mass index
(BMI) and HbA1c, the most recent record before the start of
follow-up was used to classify patients at baseline.
Subsequently, obesity (BMI30 kg/m2) and increased HbA1c
level (>75mmol/mol) were determined based on the most
recent measurement at the start of each interval. We used
stepwise model building for adjustment for potential con-
founders. In Model 1, we adjusted for all potential confound-
ers, while in Model 2 we performed additional adjustment for
number of years of past exposure to non-glargine insulins
before the start of glargine as a continuous variable, to adjust
for the potential effect of past exposure to non-glargine
insulins on the association between glargine use and breast
cancer risk among switchers. We evaluated the linearity
assumption by adding a squared term to the model, together
with the continuous variable.
Statistical analysis
Multivariate Cox proportional hazards models were used to
estimate the hazard ratio (HR) and 95% confidence intervals
(CI) of breast cancer associated with the use of glargine, with
survival time in 30-day intervals as the time variable. For all
models, ‘never use’ of glargine was used as the reference cat-
egory. In addition to the analyses stratified by categories of
cumulative duration of use, we performed p-trend analyses,
where cumulative exposure to insulins was included as a con-
tinuous variable.
In a sensitivity analysis, an extended category of cumula-
tive duration of glargine exposure was added – ‘0–1 years’,
‘1–3 years’, or ‘3–5 years’, and ‘>5 years’ – when study power
Figure 1. Schematic representation of exposure measures used. The basic time-dependent design considers a patient exposed from the first prescription of glargine
onward. Cumulative exposure measures were included as a refinement, where patients are stratified by (a) cumulative exposure to insulin glargine during follow-up,
(b) duration of exposure to other insulin types before the start of glargine treatment, and (c) stratified to insulin-na€ıve starters of glargine and patients switched to
glargine.
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was sufficient. In a separate analysis, the cumulative duration-
response effect was studied among glargine users independ-
ently. Here, patients started on glargine were censored at the
time a different insulin type was prescribed. In this sensitivity
analysis, the lowest category of cumulative exposure was
taken as the reference.
All data management and statistical analyses (PROC
PHREG) were conducted using SAS 9.2 (SAS Institute Inc, Cary,
NC, USA).
Results
For this study, we selected 12 468 female incident insulin
users for our final study cohort (Supplemental Figure A, avail-
able online at http://www.informahealthcare.com). Baseline
characteristics of new users of insulin who received a first
prescription for glargine (n¼ 3858) or non-glargine insulins
(n¼ 8610) are shown in Table 1. The median duration of
follow-up was comparable between the glargine and non-
glargine starters (5.0 vs. 5.1 years), as was the median dur-
ation of insulin exposure during follow-up; 2.6 years of
glargine use among glargine starters, and 3.0 years of non-
glargine insulin use among non-glargine starters. Glargine
starters were in general older at baseline (median age of 66
vs. 61 years). Of the non-glargine starters, the majority
received a first prescription for insulin aspart (44.6%) or
human insulin (39.4%). Glargine starters in general received
NIADs in the year prior to baseline (95.3%).
Risk of breast cancer
During a total follow-up of 66 151 person years, 186 breast
cancer cases occurred. Of these, 76 occurred in patients
after exposure to glargine (3.0 per 1000 person years), and
110 in patients never exposed to glargine (2.7 per 1000
person years). In our model adjusted for potential con-
founders (Model 1), no discernible increase in breast cancer
risk was associated with ‘ever use’ of glargine (HR 1.06, 95%
CI 0.79–1.44), as compared to ‘never use’ (Table 2). When
adjusted for years of exposure to other insulins before the
start of glargine treatment (Model 2), no risk difference was
observed (HR 0.98, 95% CI 0.72–1.35).
Cumulative exposure measures
Stratification by cumulative duration of exposure to glargine
during follow-up (Figure 1a, Table 2) did not show an associ-
ation with breast cancer risk (p-trend¼ 0.83 in Model 1). Even
when cumulative glargine use of over five years was modeled
as a separate category (sensitivity analysis), no significant dif-
ference in risk was observed (HR 1.26, 95% CI 0.64–2.47 in
Model 1).
Among switchers, stratification by prior exposure to non-
glargine insulins at the start of glargine treatment (Figure 1b,
Table 2) showed a linear trend with increasing years of prior
exposure to non-glargine insulins (p-trend¼ 0.02 in Model 1).
Here, a significant three-fold increase in breast cancer risk
was observed in switchers with a history of non-glargine
insulin use of more than three years, as compared to women
never exposed to glargine (HR 3.17, 95% CI 1.28–7.84).
Among insulin-na€ıve women (Figure 1c, Table 3), no
increased breast cancer risk was associated with ‘ever use’ of
glargine (HR 0.99, 95% CI 0.71–1.37). Also, no trend with
cumulative duration of glargine exposure was observed
(p-trend¼ 0.91, HR¼ 0.99, 95% CI 0.90–1.10 per additional year
of exposure). After additional stratification (sensitivity analysis),
no increased breast cancer risk was associated with 5 years
of cumulative exposure (HR¼ 1.06, 95% CI 0.48–2.33).
Among switchers, a slight, non-significantly increased
breast cancer risk was associated with ‘ever use’ of glargine
Table 1. Baseline characteristics of incident insulin users started on insulin glar-
gine, non-glargine insulin, or both.
Glargine cohort Non-glargine cohort
(n¼ 3858) (n¼ 8610)
Follow-up (median, IQR) 5.0 (3.0–7.5) 5.1 (3.1–7.9)
Maximum 11.0 11.2
Age (median, IQR) 66 (55–76) 61 (45–72)
<30 43 (1.1) 165 (1.9)
30–40 183 (4.7) 1387 (16.1)
40–50 381 (9.9) 1025 (11.9)
50–60 736 (19.1) 1476 (17.1)
60–70 923 (23.9) 1894 (22.0)
70–80 937 (24.3) 1791 (20.8)
>80 655 (17.0) 872 (10.1)
BMI (median, IQR) 30.4 (26.0–35.3) 30.4 (25.9–35.4)
<20 125 (3.2) 337 (3.9)
20–25 589 (15.3) 1326 (15.4)
25–30 1085 (28.1) 2137 (24.8)
30–35 962 (24.9) 2054 (23.9)
>35 962 (24.9) 2086 (24.2)
Missing 135 (3.5) 670 (7.8)
HbA1c (median, IQR) 79.1 (67.1–95.5) 78.0 (63.8–94.4)
<32mmol/mol 8 (0.2) 39 (0.5)
32–64mmol/mol 689 (17.9) 1756 (20.4)
64–75mmol/mol 815 (21.1) 1250 (14.5)
>75mmol/mol 2104 (54.5) 3796 (44.1)
Missing 242 (6.3) 1769 (20.5)
Smoking habit
Non-smoker 1900 (49.2) 4187 (48.6)
Current smoker 550 (14.3) 1398 (16.2)
Ex-smoker 983 (25.5) 2051 (23.8)
Missing 425 (11.0) 974 (11.3)
Medical diagnosis (ever before)
Other cancer 255 (6.6) 583 (6.8)
Oophorectomy 6 (0.2) 25 (0.3)
Type of insulin (at baseline)
Glargine 3858 (100.0) 0 (0.0)
Non-glargine 2888 (7.5) 8610 (100.0)
Human insulin 12 (0.3) 3394 (39.4)
Aspart 207 (5.4) 3841 (44.6)
Detemir 1 (0.0) 1186 (13.8)
Glulisine 32 (0.8) 16 (0.2)
Lispro 38 (1.0) 656 (7.6)
Other insulins 0 (0.0) 27 (0.3)
Medication use (year prior to index)
NIADs
None 220 (5.7) 2093 (24.3)
Metformin 3014 (78.1) 5233 (60.8)
Sulfonylureas 3158 (81.9) 5174 (60.1)
Thiazolidinediones 1331 (34.5) 2101 (24.4)
Other* 518 (13.4) 826 (9.6)
HRT 286 (7.4) 594 (6.9)
Statins 2701 (70.0) 4722 (54.8)
BMI: body mass index; HbA1c: glycated hemoglobin; HRT: hormone replacement
therapy; IQR: interquartile range; NIAD: non-insulin antidiabetic drug.
*Glinides, alpha-glucosidase inhibitors, glucogon-like peptide 1 agonists, dipep-
tidyl peptidase-4 inhibitors, guar gum.
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(HR¼ 1.40, 95% CI 0.83–2.34). Moreover, a non-significant
trend was observed with cumulative number of years of glar-
gine exposure (p-trend¼ 0.24, HR¼ 1.10, 95% CI 0.94–1.29
per additional year of exposure in Model 1). Adjustment for
number of years of exposure to non-glargine insulins before
the start of glargine treatment (Model 2) resulted in notice-
able reductions in risk estimates. The HR for ‘ever use’ of glar-
gine in switchers was reduced to 0.97 (95% CI 0.47–1.99),
while the HR for the highest category of cumulative glargine
exposure was reduced from 1.58 (95% CI 0.63–3.94) to 1.14
(95% CI 0.42–3.09) (Table 3). In addition, the non-significant
trend with cumulative number of years of glargine exposure
disappeared after adjustment for cumulative number of years
of exposure to non-glargine insulins (p-trend¼ 0.99,
HR¼ 1.00, 95% CI 0.91–1.10 per additional year of exposure,
Model 2 (not shown)). In this model, a significant trend was
observed with number of years of prior non-glargine insulin
exposure (p-trend¼ 0.02, HR¼ 1.24, 95% CI 1.03–1.50 per
additional year of exposure, Model 2) (not shown).
Results from our sensitivity analysis that censored glargine
insulin users if any other type of insulin was initiated, also
showed no trend with cumulative duration of use (Supplemental
Table A).
Discussion
In this cohort study among women with type 2 diabetes
newly started on insulin, glargine use was not associated with
an increased risk of breast cancer after a median follow-up of
Table 2. Hazard ratios for breast cancer associated with the use of insulin glargine, stratified by cumulative duration of glargine use during follow-up and by
cumulative exposure to other insulins before the initiation of glargine therapy.
Events Person years IR Age adj. HR (95% CI) Model 1 HR (95% CI)* Model 2 HR (95% CI)†
Use of non-glargine insulins‡ 110 40912.6 2.7 1 Reference 1 Reference 1 Reference
Ever use of glargine 76 25238.5 3.0 1.08 0.81–1.45 1.06 0.79–1.44 0.98 0.72–1.35
Cumulative glargine use§,k
<1 year 29 8621.0 3.4 1.11 0.74–1.68 1.15 0.76–1.76 1.05 0.68–1.62
1–3 years 26 8994.3 2.9 1.02 0.66–1.56 0.99 0.64–1.53 0.91 0.58–1.42
>3 years 21 7623.1 2.8 1.12 0.69–1.81 1.05 0.64–1.70 0.99 0.61–1.62
3–5 years 11 4550.0 2.4 0.97 0.52–1.81 0.91 0.48–1.71 0.86 0.45–1.61
>5 years 10 3073.1 3.3 1.37 0.70–2.67 1.26 0.64–2.47 1.22 0.62–2.39
Cumulative prior non-glargine use¶,#
None 59 19923.3 3.0 1.03 0.75–1.41 0.99 0.71–1.37
0–3 years 12 4628.8 2.6 1.08 0.59–1.96 1.14 0.62–2.07
>3 years** 5 686.4 7.3 3.11 1.26–7.67 3.17 1.28–7.84
adj: adjusted; CI: confidence interval; HR: hazard ratio; IR: incidence rate in events/1000 person years.
*Model 1, adjusted for potential confounders; i.e. obesity, smoking, alcohol use, HbA1c>75mmol/mol, history of oophorectomy or other cancer types, and use of
metformin, sulfonylureas, glitazones, hormone replacement therapy, or statins;
†Model 2, additional adjustment for number of years of exposure to other non-glargine insulin(s) at the start of glargine treatment as a continuous variable;
‡Person-time without any history of insulin glargine use;
§Cumulative number of years of current exposure to insulin glargine during follow-up;
¶Cumulative number of years of current exposure to non-glargine insulins before the start of glargine treatment;
**Median past exposure 4.4 (interquartile range, 3.6–5.6 years; maximum, 10.3 years).
Linear trends based on the slope of continuous cumulative number of years of current exposure in Model 1:
kp-trend¼ 0.83, (HR¼ 1.01, 95% CI 0.92–1.10), for cumulative current exposure to glargine;
#p-trend¼ 0.02, (HR¼ 1.24, 95% CI 1.03–1.49), for cumulative current exposure to non-glargine insulin(s).
Table 3. Hazard ratios for breast cancer associated with the use of insulin glargine, among insulin-na€ıve glargine users and glargine users with prior exposure to
other insulins, stratified by categories of cumulative glargine use and adjusted for use of other insulins before the start of glargine.
Events Person years IR Age adj. HR (95% CI) Model 1 HR (95% CI)* Model 2 HR (95% CI)†
Use of non-glargine insulin‡ 110 40912.6 2.7 1 Reference 1 Reference 1 Reference
Ever use of glargine 76 25238.5 3.0 1.08 0.81–1.45 1.06 0.79–1.44 0.98 0.72–1.35
Insulin-na€ıve glargine users§ 59 19923.3 3.0 1.02 0.74–1.41 0.99 0.71–1.37
Cumulative glargine usek
<1 year 23 6759.8 3.4 1.09 0.69–1.71 1.11 0.69–1.77
1–3 years 20 7119.9 2.8 0.96 0.59–1.54 0.91 0.56–1.49
>3 years 16 6043.6 2.6 1.05 0.61–1.80 0.96 0.56–1.66
3–5 years 9 3610.5 2.5 0.97 0.49–1.93 0.90 0.45–1.80
>5 years 7 2433.0 2.9 1.18 0.54–2.57 1.06 0.48–2.33
Patients switched to glargine¶ 17 5315.2 3.2 1.33 0.80–2.22 1.40 0.83–2.34 0.97 0.47–1.99
Cumulative glargine use#
<1 year 6 1861.2 3.2 1.24 0.55–2.83 1.32 0.58–3.03 0.84 0.31–2.31
1–3 years 6 1874.4 3.2 1.31 0.57–2.98 1.36 0.59–3.10 0.89 0.33–2.37
>3 years 5 1579.6 3.2 1.59 0.64–3.95 1.58 0.63–3.94 1.14 0.42–3.09
adj: adjusted; CI: confidence interval; HR: hazard ratio; IR: incidence rate in events/1000 person years.
*Model 1, adjusted for potential confounders; i.e. obesity, smoking, alcohol use, HbA1c>75mmol/mol, history of oophorectomy or other cancer types, and use of
metformin, sulfonylureas, glitazones, hormone replacement therapy, or statins;
†Model 2, additional adjustment for number of years of exposure to other non-glargine insulin(s) at the start of glargine treatment as a continuous variable;
‡Person-time without any history of insulin glargine use;
§Patients without past cumulative exposure to other insulins at the start of glargine therapy;
¶Patients with past cumulative exposure to other insulins at the start of glargine therapy.
Linear trends based on the slope of continuous cumulative number of years of current exposure in Model 1:
kp-trend¼ 0.91, (HR¼ 0.99, 95% CI 0.90–1.10), for cumulative years exposed to glargine;
#p-trend¼ 0.24, (HR¼ 1.10, 95% CI 0.94–1.29), for cumulative years exposed to glargine.
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five years as compared to use of other insulins. However, a
difference in breast cancer risk between insulin-na€ıve new
users of glargine and women who switched to glargine after
having used other types of insulin was observed. More specif-
ically, no association between glargine use (either in general
or with cumulative use) and breast cancer risk was seen
among insulin-na€ıve new users of glargine, even after five
cumulative years of glargine exposure. In contrast, a non-sig-
nificant increase in breast cancer risk was found among
patients who switched to glargine, depending on the number
of years of past insulin use. That is, a significant trend was
observed for each additional year of non-glargine exposure
before the start of glargine treatment.
Our results regarding insulin-na€ıve patients (i.e. without
prior exposure to other insulins) are in agreement with those
from most observational studies that used cumulative expos-
ure measures. In the previous studies, four out of five did not
show an association between cumulative duration of glargine
use and breast cancer risk among insulin-na€ıve starters of
glargine [13,15–17]. The study by Habel et al. (2013) did
report an increased breast cancer risk associated with
extended duration (2 years) of use (HR¼ 1.6, 95% CI
1.0–2.8) [14]. This result might be a chance finding, as with a
median duration of glargine use of 1.2 years they were
unable to assess patterns of risk with longer duration of use.
In fact, all previous studies among insulin-na€ıve glargine users
were limited by insufficient study power to robustly estimate
effects of long-standing (>3 years) glargine exposure.
Moreover, our results are also in line with those from clinical
trials among new users of insulin that consistently showed no
increased cancer risk associated with glargine exposure
[21–23]. The ORIGIN trial, with a median follow-up of 6.2
years, found no increased risk of breast cancer among
patients assigned to glargine versus standard care. However,
with only 28 breast cancer cases in both treatment arms,
study power was limited [22].
Among patients switched to glargine after having used
other insulins, we observed a non-significant increase in risk
associated with glargine use. This result is in line with that
of Suissa et al. (2011) who reported a significant risk increase
associated with glargine use after five years or more among
switchers [13]. However, the 2.7-fold risk increase (95% CI
1.1–6.5) found in their study is much larger than the one
observed in our study. Conversely, the only other study that
included switchers, found no increased risk associated with
duration of glargine use, but was limited by a relatively short
follow-up for glargine users (median of 2.3 years) [14]. In our
study, we observed that breast cancer risk increased with
each added year of non-glargine insulin use before the start
of glargine (i.e. effect modification). Neither of the previous
studies assessed the effect of past insulin exposure on the
association between glargine use and breast cancer risk.
Suissa et al. are thus far the only ones to acknowledge that
duration of insulin use before the start of glargine use
should be taken into account. However, by matching on dur-
ation of past use, the amount of a potential effect was not
measured.
Extensive past use (3 years) of non-glargine insulins was
associated with a three-fold increase in breast cancer risk
among patients switched to glargine. However, when consid-
ering latency periods and the longer duration of type 2 dia-
betes and treatment thereof [24], it is impossible to attribute
this excess risk among switchers to a single factor (i.e. glar-
gine use). Nonetheless, this result sheds some light on the
dynamics linked to the apparent difference in breast cancer
risk seen in insulin-na€ıve patients started on glargine and
switchers with past exposure to other insulins. The import-
ance of taken prior use of other insulins into account was
demonstrated by the noticeable reduction in all risk estimates
for breast cancer associated with glargine use after adjust-
ment for the number of years previously exposed to other
insulins.
Alternative explanations for the difference in breast cancer
risk associated with glargine use between insulin-na€ıve start-
ers of glargine and switchers may entail that total duration of
insulin use (or diabetes duration), rather than exposure to any
particular insulin type, is associated with an increased risk of
breast cancer. In addition, patients switched to glargine may
differ from insulin-na€ıve patients started on glargine. If glar-
gine is used as an add-on in prevalent insulin users with
poorly controlled blood glucose levels, a possible variation in
background risk might be introduced. Such a dynamic could
lead to channeling and potential protopathic bias among
switchers. This alternative hypothesis might be evaluated in
future studies.
Major strengths of our study include the use of time-
dependent exposure measures based on prescription data to
determine insulin exposure. This definition minimizes expos-
ure misclassification and more accurately reflects real expos-
ure than time since the start of follow-up, as used in previous
studies. In addition, as only incident insulin users (1 year
without any insulin use at baseline) were included, we had
comprehensive information on insulin use for patients
included in the cohort. In patients who switched to glargine
during follow-up, we were able to determine the effect of
past insulin use on the association between glargine use and
breast cancer risk. To our knowledge, we are the first to
assess this effect. Furthermore, we had three additional years
of follow-up as compared to the study by Suissa et al. and
were thereby able to determine breast cancer risk estimates
for long-standing glargine use in insulin-na€ıve patients.
Several limitations of our study should be noted as well.
First of all, the comparator consisted of all other (non-
glargine) insulins. This category included both short- and
long-acting insulins, resulting in a heterogeneous reference
group. However, it can be regarded as a relevant reference
group when you want to assess glargine associated risks ver-
sus the other treatment options available. Conversely, this
approach did not allow for direct comparisons between long-
acting insulin types. Second, our models did not account for
any additional effects of combined use of both glargine and
non-glargine insulins. Ideally, combined use should be con-
sidered as a separate category. Also, we were unable to
make direct comparisons between glargine and non-glargine
insulin users with the same duration of exposure. Third, we
did not take latency into account, as follow-up time was
insufficient to incorporate a sensible latency period for breast
cancer. Fourth, as the cohort was restricted to new users of
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insulin at cohort entry, study power to analyze effects with
cumulative duration of use was limited for the group of
switchers, hindering further stratification by strata of cumula-
tive years of past non-glargine insulin use. Fifth, as CPRD cov-
ers a dynamic patient population (i.e. 7% of the total UK
population), patients who transfer to a general practitioner
who does not provide data to CPRD are lost to follow-up.
Finally, when fitting several exposure models on the same
data, focus should not be on individual significant results, but
the total of analyses should be seen in perspective and inter-
preted together [25].
In conclusion, exposure to insulin glargine did not appear
to be associated with an increased breast cancer risk in insu-
lin-na€ıve patients. Our results, however, do indicate an associ-
ation between glargine use and breast cancer among
patients previously treated with other insulins before the start
of glargine. Glargine use in patients with extensive past
exposure to other insulin types was associated with a three-
fold increased risk. Therefore, observational studies need to
take past exposure to other insulins into account when study-
ing breast cancer risk associated with glargine use. Future
studies should consider whether this excess risk of breast can-
cer observed in patients switched to glargine is caused by
protopathic bias.
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